Value proposition

Generate human-specific efficacy and safety data with PhysioMimix® Single- and Multi-organ microphysiological systems.

CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery.

Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals.

Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates.

It starts here.


Organ-on-a-chip, Hepatitis B, drug discovery, liver disease, containment level 3 laboratory, microfluidic cell culture, precision biology, non-alcoholic steatohepatitis, Organ-on-Chip, Preclinical drug discovery, Microphysiological systems, Safety Toxicology, non-alcoholic fatty liver disorder, Contract Research Services, PhysioMimix OOC, Drug-induced liver injury, ADME, disease modeling, 3D cell culture, Aminal alternative, New Alternative approaches, COVID 19, Drug absorption, Drug metabolism, Bioavailability, Respiratory infection, and DILI